newsfilter
← Earnings
Earnings Releases·

TherapeuticsMD — Third Quarter 2026 Earnings Summary

  • Net income from continuing operations rose to $501 thousand ($0.04 per share) in Q3 2026 from $50 thousand in the prior year period, driven by a 60.6% year-over-year increase in license revenues to $1.3 million.
  • Total operating expenses increased 5.6% to $1.7 million, primarily due to higher legal and professional fees, while cash and cash equivalents stood at $10.4 million as of September 30, 2026.
  • The Company expects to recognize additional revenue from a net sales milestone related to IMVEXXY sales during the three months ending December 31, 2026, following notification from licensee Knight.
  • Management is evaluating strategic alternatives, including potential acquisitions, mergers, or asset sales, though no timetable has been established for these initiatives.
  • The Company faces ongoing risks regarding commercial success of licensed products, potential Nasdaq listing status maintenance, and the outcome of disputes with Mayne Pharma.
Company
THERAPEUTICSMD INC
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic